Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBITDA (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of EBITDA data on record, last reported at -$33.1 million in Q3 2025.

  • For Q3 2025, EBITDA fell 112.59% year-over-year to -$33.1 million; the TTM value through Sep 2025 reached -$99.9 million, up 29.43%, while the annual FY2024 figure was -$136.7 million, 15.48% down from the prior year.
  • EBITDA reached -$33.1 million in Q3 2025 per TNXP's latest filing, down from -$28.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$15.6 million in Q3 2024 and bottomed at -$77.3 million in Q2 2024.
  • Average EBITDA over 3 years is -$30.2 million, with a median of -$28.1 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 166.59% in 2024, then surged 63.4% in 2025.
  • A 3-year view of EBITDA shows it stood at -$27.3 million in 2023, then increased by 17.74% to -$22.5 million in 2024, then crashed by 47.1% to -$33.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$33.1 million in Q3 2025, -$28.3 million in Q2 2025, and -$16.1 million in Q1 2025.